Hasanfatta¹* and Gauresh Indulkar²

¹MBBS, DNB General Medicine, DNB Cardiology, Aster Jubilee Medical Complex, Dubai, UAE
²MBBS, MRCEM, Gleneagles Hospital, Urgent Care Centre, Singapore

*Corresponding Author: Naeem Hasanfatta, MBBS, DNB General Medicine, DNB Cardiology, Aster Jubilee Medical Complex, Dubai, UAE.

Received: November 06, 2024; Published: December 16, 2024

Abstract

Heart Failure and its subtype Heart Failure with Preserved Ejection Fraction (HFPEF) represent a vexing pathophysiological conundrum. Till date the exact mechanism of heart failure progression and HFPEF has not been clearly defined. However recent research into cardiac energetics and the suprising success of drugs like SGLT2 Inhibitors show us that our understanding of heart failure pathophysiology needs to be redefined in terms of metabolic rather than structural abnormality. We seek to propose a novel cyclical model explaining Diastolic Dysfunction in terms of energy deficit and its relation with coronary microcirculation insufficiency to explain progressive HFPEF and likely mechanism of action of SGLT2 Inhibitors to interrupt it.

 Keywords: Heart Failure; Calcium

References

1. Heidenreich PA., et al. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines”. Circulation (2022).
2. Palm CL., et al. “Short-Chain Fatty Acids in the Metabolism of Heart Failure – Rethinking the Fat Stigma”. Frontiers in Cardiovascular Medicine (2022).
3. Kolwicz SC Jr., et al. “Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes”. Circulation Research (2013): 603-616.
4. van R., et al. “Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion”. European Journal of Heart Failure7 (2014): 772-777.
5. Ceia F., et al. “Prevalence of chronic heart failure in Southwestern Europe: the EPICA study”. European Journal of Heart Failure4 (2002): 531-539.
6. Bleumink G., et al. “Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study”. European Heart Journal18 (2004): 1614-1619.
7. Koh A., et al. “A comprehensive population-based characterization of heart failure with mid-range ejection fraction”. European Journal of Heart Failure12 (2017): 1624-1634.
8. Kane G., et al. “Progression of left ventricular diastolic dysfunction and risk of heart failure”. JAMA 8 (2011): 856-863.
9. BALLINGER W., et al. “Anaerobic metabolism of heart”. Circulation Research 11 (1962): 681-685.
10. Opie L. “Metabolism of the heart in health and disease. I”. American Heart Journal5 (1968): 685-698.
11. Rowe GC., et al. “PGC-1 Coactivators in Cardiac Development and Disease”. Kelly DP, ed. Circulation Research (2010): 825-838.
12. Ventura‐Clapier R., et al. “Energy metabolism in heart failure”. The Journal of Physiology (2004): 1-13.
13. Lopaschuk GD., et al. “Myocardial Fatty Acid Metabolism in Health and Disease”. Physiological Reviews (2010): 207-258.
14. Lopaschuk GD., et al. “Cardiac Energy Metabolism in Heart Failure”. Circulation Research (2021): 1487-1513.
15. Breckenridge RA., et al. “Hypoxic Regulation of Hand1 Controls the Fetal-Neonatal Switch in Cardiac Metabolism”. Tian R, ed. PLoS Biology (2013): e1001666.
16. Taegtmeyer H., et al. “Return to the fetal gene program: a suggested metabolic link to gene expression in the heart”. Annals of the New York Academy of Sciences 1188 (2010): 191-198.
17. Su Z., et al. “Adaptive Cardiac Metabolism Under Chronic Hypoxia: Mechanism and Clinical Implications”. Frontiers in Cell and Developmental Biology 9 (2021): 625524.
18. Sorokina N., et al. “Recruitment of Compensatory Pathways to Sustain Oxidative Flux With Reduced Carnitine Palmitoyltransferase I Activity Characterizes Inefficiency in Energy Metabolism in Hypertrophied Hearts”. Circulation (2007): 2033-2041.
19. HEATHER L., et al. “Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart”. Cardiovascular Research (2006): 430-437.
20. Osorio JC., et al. “Impaired Myocardial Fatty Acid Oxidation and Reduced Protein Expression of Retinoid X Receptor-α in Pacing-Induced Heart Failure”. Circulation (2002): 606-612.
21. Bedi KC Jr., et al. “Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure”. Circulation (2016): 706-716.
22. Dávila-Román VG., et al. “Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy”. Journal of the American College of Cardiology (2002): 271-277.
23. Lai L., et al. “Energy Metabolic Reprogramming in the Hypertrophied and Early Stage Failing Heart”. Circulation: Heart Failure (2014): 1022-1031.
24. Karwi QG., et al. “Loss of Metabolic Flexibility in the Failing Heart”. Frontiers in Cardiovascular Medicine (2018).
25. He L., et al. “Carnitine Palmitoyltransferase-1b Deficiency Aggravates Pressure Overload–Induced Cardiac Hypertrophy Caused by Lipotoxicity”. Circulation (2012): 1705-1716.
26. Kalsi KK., et al. “Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy”. European Journal of Clinical Investigation (1999): 469-477.
27. Little S., et al. “The rates of Ca2+ dissociation and cross-bridge detachment from ventricular myofibrils as reported by a fluorescent cardiac troponin C”. Journal of Biological Chemistry33 (2012): 27930-27940.
28. Selby D., et al. “Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction”. Journal of the American College of Cardiology2 (2011): 147-154.
29. Pouleur H., et al. “Focus on diastolic dysfunction: a new approach to heart failure therapy”. British Journal of Clinical Pharmacology 28 (1989): 41S-52S.
30. van H., et al. “Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension”. Circulation1 (2008): 43-51.
31. Meyer M., et al. “Relationship of exercise capacity and left ventricular dimensions in patients with a normal ejection fraction. An exploratory study”. PLoS One3 (2015): e0119432.
32. BATE-SMITH E and BENDALL J. “Factors determining the time course of rigor mortis”. Journal of Physiology1-2 (1949): 47-65.
33. Tian R., et al. “Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart”. Journal of Clinical Investigation (1997): 745-751.
34. Bernard M., et al. “On the Relations among ATP Hydrolysis, Cation Accumulation, and Diastolic Dysfunction”. In: Lorell BH, Grossman W, eds. Diastolic Relaxation of the Heart: The Biology of Diastole in Health and Disease. Springer US; (1994): 73-78.
35. Tian R., et al. “Failure to Maintain a Low ADP Concentration Impairs Diastolic Function in Hypertrophied Rat Hearts”. Circulation (1997): 1313-1319.
36. Duncker D and Bache R. “Regulation of coronary blood flow during exercise”. Physiology Review3 (2008): 1009-1086.
37. Feigl E. “Coronary physiology”. Physiology Review1 (1983): 1-205.
38. Tune JD. “Coronary Circulation”. Colloquium Series on Integrated Systems Physiology: From Molecule to Function (2014): 1-189.
39. Downey J. “Myocardial contractile force as a function of coronary blood flow”. American Journal of Physiology 1 (1976): 1-6.
40. Downey J., et al. “Effects of myocardial strains on coronary blood flow”. Circulation Research3 (1974): 286-292.
41. Downey J and Kirk E. “Distribution of the coronary blood flow across the canine heart wall during systole”. Circulation Research2 (1974): 251-257.
42. Downey J and Kirk E. “Inhibition of coronary blood flow by a vascular waterfall mechanism”. Circulation Research6 (1975): 753-760.
43. Galderisi M., et al. “Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy”. Italian Heart Journal9 (2001): 677-684.
44. Konerman M., et al. “Reduced Myocardial Flow Reserve Is Associated With Diastolic Dysfunction and Decreased Left Atrial Strain in Patients With Normal Ejection Fraction and Epicardial Perfusion”. Journal of Cardiac Failure 2 (2018): 90-100.
45. Taqueti V., et al. “Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction”. European Heart Journal10 (2018): 840-849.
46. Hong D., et al. “Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function on Cardiovascular Death”. Journal of the American Heart Association 3 (2023): e027690.
47. Ohara T and Little W. “Evolving focus on diastolic dysfunction in patients with coronary artery disease”. Current Opinion in Cardiology 6 (2010): 613-621.
48. Prasad S., et al. “Determinants of Diastolic Dysfunction Following Myocardial Infarction: Evidence for Causation Beyond Infarct Size”. Heart Lung Circulation12 (2020): 1815-1822.
49. Maragiannis D., et al. “Association of Left Ventricular Diastolic Dysfunction with Subclinical Coronary Atherosclerotic Disease Burden Using Coronary Artery Calcium Scoring”. Journal of Atherosclerosis and Thrombosis 12 (2015): 1278-1286.
50. Galderisi M., et al. “Independent association of coronary flow reserve with left ventricular relaxation and filling pressure in arterial hypertension”. American Journal of Hypertension9 (2008): 1040-1046.
51. Kagaya Y., et al. “Glycolytic inhibition: effects on diastolic relaxation and intracellular calcium handling in hypertrophied rat ventricular myocytes”. Journal of Clinical Investigation6 (1995): 2766-2776.
52. Doenst T., et al. “Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload”. Cardiovascular Research3 (2010): 461-470.
53. Luptak I., et al. “Decreased ATP production and myocardial contractile reserve in metabolic heart disease”. Journal of Molecular and Cellular Cardiology 116 (2018): 106-114.

Citation

Citation: Naeem Hasanfatta and Gauresh Indulkar. “Diastolic Dysfunction and Cardiac Energy Deficit: Understanding Progressive Heart Failure in the Light of SGLT2 Inhibitors”.Acta Scientific Medical Sciences 9.1 (2025): 71-76.

Copyright

Copyright: © 2025 Naeem Hasanfatta and Gauresh Indulkar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.